Adiponectin (ADIPOQ) is a hormone primarily synthesized Background: by adipocytes and encoded by the gene, which exerts ADIPOQ anti-inflammatory, antiatheratogenic and insulin sensitizing functions. It has been shown that its plasma concentrations are decreased in individuals with metabolic syndrome (MS) and type 2 diabetes mellitus (DM2), which could be due to variations in the gene coding for this protein. The aim of this study was to detect the +45 T>G polymorphism of the gene in ADIPOQ subjects with DM2 and MS in Maracaibo municipality, Zulia state, Venezuela.
in the control group than in the MS-DM2 group. Regarding the individuals with T/G and G/G genotypes, statistically significant lower mean values were found for fasting glucose, total cholesterol, triacylglycerides, abdominal circumference, and for the medians of systolic and diastolic blood pressure. Odds ratio were calculated for the presence or absence of MS and DM2.
The results suggested that the presence of the G allele Conclusions: exerts a protective effect on the carrier individuals, thus avoiding the appearance of the aforementioned metabolic alterations. 
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Introduction
Adiponectin contains 244 amino acids 1 and this protein is expressed almost exclusively in white adipose tissues where it has anti-diabetic, anti-inflammatory, and anti-atherogenic properties in addition to cardioprotective effects 2, 3 . It is considered one of the most abundantly secreted adipokines by the adipocyte, because its plasma concentrations in humans vary between 5-30 μg/ml, and although this values vary according to sex (generally higher in women) 4 , adiponectin represents 0.01% of total plasma proteins 3 . Unlike other known adipokines, its levels are decreased in insulin-resistance associated states, such as obesity, type 2 diabetes mellitus (DM2) and metabolic syndrome 5 .
Metabolic syndrome (MS) is a complex of interrelated risk factors for the development of cardiovascular diseases and diabetes mellitus (DM) 6 . The prevalence of MS in the world is very high; 45% of the population over 50 years old and about 20% of the population under 50 years of age have MS 7 . Patients with MS have twice the risk of developing cardiovascular disease in 5 to 10 years after being diagnosed 8 , increasing the risk of myocardial infarction 9 .
Epidemiological studies conducted in the U.S have shown that the general prevalence of MS is 24% in Caucasian populations, which increases according to age to more than 30% in people over 50 years of age and more than 40% in people over 60 years of age 10 . In a study carried out in Maracaibo, Venezuela, the prevalence of MS was 42.7%, presenting men at a higher risk when compared with women; as age increases, the risk also increases progressively. Similarly, diabetic individuals had up to 4 times higher risk of suffering from MS 11 .
Diabetes mellitus is one of the main causes of morbidity and mortality, as well as an important cardiovascular risk factor and a poor prognosis in patients with established cardiovascular disease 12 . Its prevalence has drastically increased in the last 20 years and it is estimated that by the year 2030 the number of affected will exceed approximately 400 million people 12 , which translates into a 54% increase 13 .
Some 422 million people suffer from diabetes in the world, totaling one out of every 11 people. It is estimated that in 2012, 1.5 million people died as a direct consequence of diabetes. According to WHO projections, diabetes will be the seventh greatest cause of mortality in 2030
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. In Venezuela, according to the 2011 Ministry of Public Power of Health, diabetes mellitus represents the fourth-leading cause of death. This data corresponds with WHO data. Furthermore, diabetes mortality projections remain high over the foreseeable future 15 . In an analysis conducted on a Venezuelan population (Maracaibo City, Zulia State) about the DM2 prevalence, it was found that 8.4% of the evaluated population had the disease, which is similar to that shown in our continent, in the Carmela study, which took in consideration seven cities in Latin America, evaluating more than 11,000 individuals aged between 25 and 64 years; this study reported a general prevalence of 7%, where the one shown in Mexico City stands out (8.9%) since is higher 12 .
The serum concentration of adiponectin is reduced in individuals with obesity, DM2, insulin resistance, obesity, dyslipidemia and coronary disease 16, 17 . With an link to lower lipid oxidation, higher triglyceride content, and reduced levels of insulindependent signaling-reduced concentrations of adiponectin have been noted in the pathophysiology MS and DM2
18 .
The ADIPOQ gene is located on chromosome 3q27, consists of 3 exons and is 15.8 kb long 1 . Genetic variants in ADIPOQ can lead to substantial changes in adiponectin levels, which provides convincing evidence that subtle alterations in the genetic code can modify the levels of this hormone, large enough to significantly affect the health, as mentioned before 1 . Several studies have determined that different polymorphisms (SNPs) have been located in the adiponectin gene, which can affect both the transcription and the activity of this hormone. Among the most prominent are the polymorphisms +45 T>G, +276 G>T, -11.377 C>G and -11.391 G>A 19 .
Studies carried out in different populations, associated the +45T>G polymorphism of the ADIPOQ gene with the development of DM2, insulin resistance, obesity, coronary artery disease and hypoadiponectinemia 19 . Other studies reported that subjects with the T/G or G/G genotype at position 45 have a higher risk of developing DM2 when compared to those with T/T genotype 20 . Likewise, it has been observed that subjects who present the G allele of the +45T>G polymorphism have lower plasma levels of adiponectin 19 .
Due to such significant findings, this study aimed to determine nucleotide alterations of the ADIPOQ gene, especially the +45T>G polymorphism and its relationship with DM2 and MS, in adult individuals of the Maracaibo municipality of Venezuela. The study aimed to identify cases of people carrying the alteration indicated in this gene, which could be related to DM2 and MS. In this way, the presence of the polymorphism would serve as a predictor for the development of MS and/or DM2 in the future 16, 21 , guaranteeing the possibility that any person with a predisposing genotype can take opportune measures to prevent these diseases.
Methods
Subjects
A total of 90 adult individuals, of which 46 had MS-DM2 and 44 were healthy controls, were enrolled in this study, which was carried out from January 2015 to January 2016. Participants were recruited through a mixed strategy. Some individuals were contacted by phone while in remote locations we made contact with the community leaders in order to verify the size and organization of each neighborhood since public records prove inaccurate. After this, we proceeded to draw sectors and blocks, and then, together with the community leaders, contact the members of the selected houses directly. These individuals participated in the Metabolic Syndrome Prevalence Project The participants signed an informed consent form, where they were explained everything related to the project and the handling of their samples and tests. This research was approved by the CIEM bioethics committee and complies with the Helsinki declaration. The studied subjects were chosen since they met the predetermined inclusion criteria and with the absence of selected exclusion criteria, depicted in Table 1 . In order to make the diagnosis of MS and DM2, 2009 Consensus 6 and ADA 22 criteria was used respectively.
Anthropometry, body composition and biochemistry analysis
The following variables were measured in the subjects:
1. Waist circumference: taken with a graduated measure tape in centimeters at an equidistant point between the costal margin and the anterior superior iliac spine.
2. Body mass index: estimated by dividing the kilograms of weight by the square of the height in square meters (BMI = kg/m 2 ). A TANITA electronic scale was used to obtain the body weight. To measure the size, a height rod was used.
3. Blood pressure: measured by the auscultatory method, for which a calibrated and properly validated sphygmomanometer was used.
4. Levels of fasting glucose, total cholesterol, triacylglycerides and HDLc (cholesterol bound to high density lipoproteins): (previous fasting from 8 to 12 hours), for which 5 cm 3 of blood was drawn from each individual obtained by antecubital venipuncture, which was placed in test tubes and centrifuged to 4000 rpm for 10 minutes. After this, the serum was extracted and placed in polypropylene test tubes for subsequent freezing at -70°C. The time between taking the sample and processing did not exceed three months. To determine the interest was amplified by PCR, using this set of oligonucleotide primers: F5'-GAATGAGACTCTGCTGAGATGG-3' and R5'-TATCATGTGAGGAGTGCTTGGATG-3' to amplify the region of interest (Figure 1 ). The amplification conditions were the following: 95°C for 6 min, followed by 35 cycles of 95°C for 1 min, 45 sec at 56°C and 45 sec at 72°C and a final extension at 72°C for 5 min 24 . For the amplification reactions, taq DNA polymerase from Promega was used.
RFLP for the detection of the 45 T>G polymorphism of the ADIPOQ gene. The amplified fragment of 372bp was subjected to restriction analysis with the SmaI enzyme. A non-digested fragment (molecular weight, 372 bp) corresponded to the homozygous T/T genotype. The homozygous G/G genotype was evidenced by the presence of two fragments, one 219 bp and the other 153 bp. The product of the digestion of the heterozygous T/G genotype was evidenced by the presence of three fragments (372 bp, 219 bp and 153 bp), as shown in Figure 1 .
Statistical analysis
The statistical package SPSS for Windows, version 21.0 was used. Allelic and genotypic frequencies were calculated for the total population evaluated and for the MS-DM2 and control groups. The χ 2 test was used to compare frequencies and observed and expected values to evaluate the Hardy-Weinberg equilibrium (HWE). Means and medians were determined for biochemical, clinical and anthropometric characteristics accordingly. The normal distribution of the variables was verified by the KolmorgovSmirnov test. The comparison of the parametric variables with normal distribution was performed using Student's t-test, when 2 groups were compared and the Mann and Whitney U-test in those variables that had a non-normal distribution.
A p-value <0.05 was considered statistically significant. Likewise, a binary logistic regression was carried out in order to obtain the odd ratio adjusted to a confidence interval of 95%, to estimate the relative risk of the variable under study. A p-value <0.05 was considered statistically significant.
Results and discussion
Study population characteristics
In this study, the +45 T>G polymorphism of the ADIPOQ gene was associated with the development of MS and DM2 in adult individuals from Maracaibo City. No prior information was found on the association of that polymorphism of the ADIPOQ gene with individuals diagnosed with MS and DM2. Complete raw data are available on OSF 25 .
Clinical, biochemical and anthropometric characteristics of both groups (MS +DM2 and control patients) are shown in Table 2 . Statistically significant differences were found when comparing the means and medians in almost all studied characteristics, with the exception of height and usCRP. Most of the parameters of MS and DM2 individuals were found to be higher than in healthy controls, with exception of HDL-c levels. In line with the findings of the present study, DM2 patients in Brazil, India and Russia 18,26,27 showed similar results in clinical characteristics, such as BMI, HOMA-IR, fasting glucose, TC, TG, HDL-c, LDL-c, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Moreover, Sahli et al. 28 reported statistically significant differences in BMI, fasting glucose, TC, TG, HDL-c, LDL-c, DBP, and SBP in a Tunisian population. However, a DM2 Chinese Han population 29 , showed no significant difference when comparing height and usCRP in diabetic and healthy control groups. These differences could be related to the heterogeneity of the populations, due to the fact that they may have totally different lifestyles, including feeding, physical activity, environmental factors, and customs, among others. Table 3 depicts the allelic and genotypic frequencies of the +45T>G polymorphism of the ADIPOQ gene, in patients with MS-DM2 and healthy control patients. The T/T genotype was found in greater frequency in the total population, although patients with MS-DM2 showed a greater frequency, as described by Sahli et al. 28 in a Tunisian MS population. T/G and G/G genotypes were found in both groups but showed lower frequencies. The healthy controls showed a genotypic frequency of 27% and 5% for the T/G and G/G genotypes, respectively, which indicates that the homozygous T genotype is three times higher in healthy individuals. Other studies generated opposite results 26,27,30,31 , since the T/T genotype was found more frequently in healthy control patients than in DM2 ones.
Frequency of ADIPOQ genotypes
Allelic frequencies
Regarding the alleles, a higher frequency of the T allele was observed over the G allele in both study groups, the T allele being more frequent in the population with MS-DM2, where the Hardy-Weinberg balance χ 2 = 5.99 is met, because the observed allele frequencies are as expected. Such findings relate to the MS population studied in Tunisia 28 but differ with the type 2 diabetes mellitus individuals studied in Brazil, India and Ireland 26,27,31 since the highest frequency of the T allele occurred in the healthy control group Table 4.
Comparison of populations
As shown in Table 4 , the population that differ the most from the one characterized in this study, turned out to be the Brazilian one 26 , although Brazil is near Venezuela, the studied subjects were of Japanese ancestry; this could be the reason of such genetic differences although the lifestyles and customs are similar in both countries. Table 5 shows that there was a significant difference among waist circumference, fasting glucose, total cholesterol, triacylglycerides, LDL-c, DBP and SBP, for the T/T and T/G + G/G genotypes regarding the total population. Those that had the presence of the G allele of the polymorphism exhibited lower values except for the usCRP in which those subjects that carried the T allele had lower levels in this parameter.
Association of anthropomorphic characteristics with ADIPOQ status
On the other hand, the control population (without MS-DM2) showed statistically significant difference regarding the DBP. In the MS-DM2, a significant difference was only observed in fasting insulin levels between groups. In addition, it was demonstrated that in these groups, the subjects who presented the G allele showed lower mean values than of those without this allele (homozygous T), except for the usCRP levels, which were higher in individuals with the G allele. Potapov et al.
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obtained contradictory results in their study in a DM2 Russian population, since the fasting glucose levels showed higher values for subjects carrying the G allele, and in control subjects, a statistically significant difference was only found in SBP, which was higher in those individuals who carried the G allele.
Previous studies
Several studies have reported the behavior of several anthropometric, clinical and biochemical characteristics in their total populations concerning the +45 T>G polymorphism, finding opposite data that the one found during this study. In a non-diabetic female population in Greece 16 , fasting insulin and HOMA-IR levels were significantly lower in carriers of the rare +45G allele (T/ G+G/G), which was also evidenced in Italian individuals with or without DM2 32 , in non-diabetic individuals in Taiwan   33 , there were only significant differences in the BMI, with higher values for T allele carriers, unlike Punjab individuals 34 who those that carried the G allele displayed higher BMI and WC values.
According to Menzaghi et al.
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, the biology of these associations with anthropometric, clinical and biochemical characteristics is still unclear, for example, it is mentioned in their research that studies in animal models show that adiponectin is a potent insulin activator and modulator, in addition to regulating energy homeostasis and glucose tolerance. This relationship has also been found between the adiponectin levels in rodents and humans, which suggests that the +45 T>G ADIPOQ polymorphism can exert its action by diminishing or enhancing the expression of adiponectin, which can increase or decrease body weight and insulin resistance. In other populations, this variant may be associated with DM2, obesity and MS, whereas in other association studies, insulin resistance and DM2 are a consequence of the presence of the T allele.
Additionally, a binary logistic regression model was used to determine the influence of the +45 T/G polymorphism of the ADIPOQ gene on MS-DM2, where the odds ratio showed no association of this polymorphism as a risk factor predisposing to MS-DM2. The presence of the rare allele is considered a protection factor (Table 6 ). These findings oppose those previously reported by Stumvoll et al. 36 who studied non-diabetic Germans and recognized that the +45G allele was associated with higher IR indexes. This led to lower insulin sensitivity compared to T allele carriers while those subjects who carried the polymorphism could present a higher risk of obesity. The same phenomenon was described in diabetics and non-diabetics in Northern India 34 ; however, no association between +45 T/G polymorphism and the development of DM2 was found in Koreans individuals with and without DM2
37
. The G allele of the +45 T>G polymorphism of the ADIPOQ gene has been associated with endocrine-metabolic pathology in Chinese individuals with and without MS in a similar population, whereas in Tunisia no association of polymorphism with MS was found 28, 38 .
Although there is a lack of consistency among studies, there is evidence that the 45G allele of the ADIPOQ gene plays a protective role in MS and DM2, whereas the 45T allele behaves as a risk allele for the development of obesity and insulin resistance, which are both related to the development of MS and DM2 32, 33, 39 , consistent with the findings in this study.
The +45 T>G polymorphism of the ADIPOQ gene is a silent mutation without its own biological effect, since it is a GGT to GGG substitution, which translates to Gly15Gly. Adiponectin's role in insulin sensitivity and BMI, as well as its role in both MS and DM2 pathologies are associated with genetic alterations linked to the polymorphism-related disequilibrium. mRNA G allele transcripts vary, proving higher than those of T allele of heterozygous individuals. This suggests that promoter gene polymorphisms or other adiponectin gene regulatory elements could be involved in the decrease or increase of the expression of the studied adipokine, being able to affect the mRNA allowing the stability of the splice sites in the same, affecting the amount of circulating proteins 28, 30 . It has also been observed that haplotypes that are in ligation unbalance with one or more functional variants can affect the levels of adiponectin in plasma, producing for example a change in the secondary structure of DNA, having a major influence on transcription, processing or translation; however, this is hypothetical, since the exact genetic mechanisms responsible for the expression of the specific allele have not been elucidated yet 32 .
Conclusions
In this study, biochemical, clinical and anthropometric characteristics corresponding to MS-DM2 were determined, and statistically significant differences were found between the means and medians of all the variables evaluated, except for height and usCRP. The genotype frequency of the +45 T/G polymorphism of the ADIPOQ gene, in the total population evaluated, was 79% for the homozygous T/T variant, 18% for the heterozygous T/G variant and 3% for the homozygous G/G variant. The allelic frequencies of the +45 T/G polymorphism were 0.88 for the T allele, while only 0.12 of the evaluated individuals exhibited the G allele.
Likewise, it was found that there is a statistically significant difference between the means and medians of WC, fasting glucose, total cholesterol, triacylglycerides, LDL-c, DBP and SBP, between genotypes T/T and T/G with respect to the total population. In addition, the total population with the G allele showed lower mean values for these variables than those without this allele (homozygous T), except for the values of CRP and HDL-c, which were higher in individuals with the G allele. Overall, an association was found between the +45 T>G polymorphism of the ADIPOQ gene with MS-DM2. The results suggest that the presence of the G allele exerts a protective effect on carrier individuals, thus preventing the onset of MS and DM2. 
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Columbia University Medical Center, Columbia, USA Major concern: In table 2, there is a significant age difference between case and control, it should be a covariate. The precision of the p-value is not precise, I suggest the author try other tools for the statistical test to get higher precision. In table 3, the allele frequency of this polymorphism varied among populations. The allele frequency of G in controls matched with the Latino population frequency in gnomAD. The allele frequency of G in cases is lower than gnomAD Latino population frequency but higher than African and Finnish. So, the ancestry is very critical for such analysis. How did the author decide the ancestry of each sample? Even the cases were completely Latino descents, as the cohort is small, the confidence interval of T's AF is large, it could be possible to result in a higher frequency of T with p-value >0.001. In table 3, no association was present in the genotypic association or allelic association using a chi-square test. They also showed in table 6. In table 4, the frequency in Ireland case and controls cohort reversed with the author's cohort, they also mentioned in the text, how did the author to explain it?
Minor concern:
In the section "Frequency of ADIPOQ genotypes", it said, "the homozygous T genotype is three times higher in healthy individuals". How was it from? I saw three times heterozygous T/G, was it a typo? If yes, it was not significant at all. In table 2, I guess the age show median and interquartile range, then * should not be here. In table 4, there is a typo, G's frequency 0.08 in healthy Ireland and Tunisia study. Several typos happened in table 5, the symbol is not consistent between case and control such as p-value in age, HOMA-R, and SBP. Table 5 has duplicated information as table 2, they may be able to optimize their presentation.
5. Table 5 has duplicated information as table 2 , they may be able to optimize their presentation.
Overall, I think the writing and the calculation are correct. However, the evidence they supplied cannot support their conclusions, such as no association between case and control and contrary finding among studies. +45T>G is a polymorphism, the presence of its frequency in case and control could occasionally happen for such a small cohort. It is not convincing to draw the conclusion that the phenotypic difference resulted from +45 T>G, this could be due to other common or rare variants.
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